Status:
ACTIVE_NOT_RECRUITING
A PhaseⅠStudy of ONO-7475 in Combination With ONO-4538 and Gemcitabine Plus Nab-paclitaxel (GnP), the Standard of Care, and ONO-7475 in Combination With GnP in Patients With Pancreatic Cancer
Lead Sponsor:
Ono Pharmaceutical Co. Ltd
Conditions:
Metastatic Pancreatic Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
This study is PhaseⅠstudy to examine tolerability and safety of ONO-7475 in combination with ONO-4538 and gemcitabine plus nab-paclitaxel (GnP), the standard of care, and safety of ONO-7475 in combina...
Eligibility Criteria
Inclusion
- Patient with metastatic pancreatic cancer
- Patients have an ECOG performance status of 0 to 1
- Patients with a life expectancy of at least 6 months
Exclusion
- Patients are unable to swallow oral medications
- Patients with severe complication
Key Trial Info
Start Date :
December 6 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 31 2028
Estimated Enrollment :
87 Patients enrolled
Trial Details
Trial ID
NCT06532331
Start Date
December 6 2023
End Date
March 31 2028
Last Update
April 18 2025
Active Locations (9)
Enter a location and click search to find clinical trials sorted by distance.
1
Aichi Cancer Center
Nagoya, Aichi-ken, Japan
2
National Cancer Center Hospital East
Kashiwa-shi, Chiba, Japan
3
Kanazawa University Hospital
Kanazawa, Ishikawa-ken, Japan
4
Kanagawa Cancer Center
Yokohama, Kanagawa, Japan